spacer
home > > spring 2002 > annual review of contract research organisations
PUBLICATIONS


Annual Review of Contract Research Organisations

The total number of CROs has continued to increase in 2001 in spite of economic conditions that the CROs describe as 'tough'; globally we record 25 more CROs than at this time in 2000. The greatest growth has been of European clinical CROs, while the number of clinical CROs in North America has actually fallen marginally (see Figures 1 and 2) for the first time. In Table 1 we compare the total number of CROs in 2001 with the number in 1980. Over this 21-year period the average year-on-year growth has been 6.5 per cent (a slight increase from 2000). This increase has been driven by clinical CRO growth over the period, which has averaged 11.1 per cent in Europe and 8.4 per cent in North America.

he near double-digit growth in the number of CROs contrasts with that for contract packers and manufacturers (CPMs) which has averaged 3.6 per cent globally with almost equal growth in North America and Europe.

The deceleration of the rate of growth of CROs is clearly illustrated by the graphs of the three-year moving average of the number of additional CROs, in existence (the average of each of the three previous years' number of additional CROs), which we have plotted in Figures 3-5. In all three fields - clinical, preclinical and CPMs - the average growth rate has fallen to well below its peak level seen in and around the 1990 period.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Dr Graham Hughes, Scientific Director of Technomark Consulting Services Ltd, and Marianne O'Neill, Manager of Technomark Research

Graham Hughes is Scientific Director and a Founder of Technomark Consulting Services Limited. Over the last 15 years he has keenly observed the evolving CRO scene and seen it grow from something of a cottage industry into a global US$8 billion industry. He is also the Scientific Investment Director of Technomark Medical Ventures, a novel consulting partnership with Lloyds Development Capital, which is responsible for investing in early stage life science companies and nurturing them as they grow.

Marianne O'Neill's responsibilities include the management of the database system upon which the Technomark Registers and other Technomark publications are dependent.

She also undertakes various data gathering and market intelligence assignments on behalf of external customers as well as providing research support to all the other divisions of Technomark Consulting Services Ltd. Marianne co-ordinates the Technomark Registers Online and the Technomark Website.


spacer
Dr Graham Hughes
spacer
spacer
spacer
Marianne O'Neill's
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Discussing developments on Highly Potent APIs with industry expert, Richard Arnett for the HPAPI USA conference 2019

Ahead of the 2019 HPAPI USA Conference taking place in Boston on 21st – 22nd October, SMi caught up with Richard Arnett, Manager, Industrial Hygiene, Pharmascience who is speaking on Day Two of the agenda. Richard shared his thoughts on how the industry has developed and briefly touched on what he will be discussing in October.
More info >>

White Papers

The Flexible Factory Concept: A flexible bioprocessing platform to meet the changing needs of biomanufacturing

GE Healthcare Life Sciences

For the past several years, the biopharma industry has been buffeted by dynamic market conditions that are rapidly reshaping manufacturing requirements. These factors include: • The rise of small-market pharmaceuticals that do not require the production scale of the previous “blockbuster” drug model • Increased titers and process productivity that generate more bulk-product within a much smaller manufacturing footprint • The emergence of biosimilars and continued evolution of healthcare reform, which will increasingly pressure drug pricing and require greater cost discipline • Greater competition and shorter patent protection timelines, which will further ratchet up time-to-market pressures • Tighter capital markets that will create heightened scrutiny for all new investment projects
More info >>

 
Industry Events

World Vaccine Congress Europe

18-21 October 2020, Barcelona, Spain

The World Vaccine Congress is an award-winning series of conferences and exhibitions that have grown to become the largest and most established vaccine meeting of its kind across the globe. Our credibility is show through the prestigious scientific advisory board that spend months of hard work creating a new and topical agenda, year on year.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement